West Chester Capital Advisors Inc. Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

West Chester Capital Advisors Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,368 shares of the company’s stock after selling 65 shares during the period. Johnson & Johnson comprises about 0.8% of West Chester Capital Advisors Inc.’s holdings, making the stock its 24th largest holding. West Chester Capital Advisors Inc.’s holdings in Johnson & Johnson were worth $1,129,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Riversedge Advisors LLC raised its stake in Johnson & Johnson by 8.6% in the fourth quarter. Riversedge Advisors LLC now owns 3,664 shares of the company’s stock valued at $627,000 after buying an additional 289 shares in the last quarter. Grove Bank & Trust raised its stake in Johnson & Johnson by 1.6% in the fourth quarter. Grove Bank & Trust now owns 16,779 shares of the company’s stock valued at $2,871,000 after buying an additional 261 shares in the last quarter. LifePro Asset Management raised its stake in Johnson & Johnson by 20.8% in the fourth quarter. LifePro Asset Management now owns 5,522 shares of the company’s stock valued at $945,000 after buying an additional 951 shares in the last quarter. Adviser Investments LLC raised its stake in Johnson & Johnson by 4.0% in the fourth quarter. Adviser Investments LLC now owns 75,149 shares of the company’s stock valued at $12,856,000 after buying an additional 2,872 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its stake in Johnson & Johnson by 1.4% in the fourth quarter. Commonwealth Equity Services LLC now owns 1,736,541 shares of the company’s stock valued at $297,070,000 after buying an additional 23,765 shares in the last quarter. 68.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of analyst reports. Morgan Stanley raised their price target on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, July 8th. Credit Suisse Group lifted their target price on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Daiwa Capital Markets began coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. The Goldman Sachs Group lifted their target price on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Finally, Wells Fargo & Company lifted their target price on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $172.92 on Wednesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The firm has a market capitalization of $455.02 billion, a price-to-earnings ratio of 25.17, a price-to-earnings-growth ratio of 3.32 and a beta of 0.59. The business’s 50 day simple moving average is $175.67 and its 200-day simple moving average is $174.49.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The firm had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. During the same period in the previous year, the firm posted $2.48 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. As a group, equities analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.61%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.